Skip to main content

Table 3 Cell composition of the bronchoalveolar lavage fluid and enzyme markers of lung inflammation from CF and wild-type (WT) mice at the indicated time points after a single dose of P aeruginosa LPS with and without pre-treatment with azithromycin (10 mg/kg/day), by oral administration, for 4 weeks.

From: Azithromycin reduces spontaneous and induced inflammation in ΔF508 cystic fibrosis mice

   

Alveolar Macrophages × 104/ml

Neutrophils × 104/ml

MPO OD × 10-3/second

LDH U/L

CF

LPS 3 h

AZM-

7.9 ± 0.6

0.6 ± 0.1

21.2 ± 4.2

50.0 ± 11.5

  

AZM+

3.6 ± 0.7†

0.4 ± 0.2

30.1 ± 4.7

52.6 ± 17.6

 

LPS 24 h

AZM-

6.4 ± 0.9

130.9 ± 7.9

51.7 ± 3.7

186.0 ± 61.2

  

AZM+

6.4 ± 0.7

66.4 ± 10.3†

44.8 ± 3.3

98.2 ± 30.5

 

LPS 48 h

AZM-

38.2 ± 4.3

232.9 ± 31.9

58.8 ± 8.2

155.6 ± 31.5

  

AZM+

26.7 ± 2.4*

192.2 ± 27.0

15.4 ± 3.4‡

128.7 ± 21.8

WT

LPS 3 h

AZM-

5.0 ± 0.9

0.7 ± 0.1

17.7 ± 1.1

49.8 ± 20.6

  

AZM+

4.4 ± 0.5

1.7 ± 0.9

21.4 ± 2.0

44.0 ± 6.7

 

LPS 24 h

AZM-

5.0 ± 1.7

93.3 ± 23.3

25.8 ± 1.6

55.0 ± 22.3

  

AZM+

7.1 ± 1.7

116.4 ± 22.7

31.2 ± 3.4

70.6 ± 18.6

 

LPS 48 h

AZM-

15.7 ± 4.4

142.3 ± 25.7

64.9 ± 8.6

168.2 ± 25.3

  

AZM+

14.1 ± 2.1

146.5 ± 17.0

54.9 ± 4.9

160.8 ± 19.1

  1. Values are means ± SEM for 6–9 animals per each of the 12 subgroups. *p < 0.05; †p < 0.005; ‡p < 0.0005 for comparison of corresponding mean value vs. that obtained for the same parameter at the same time point without pre-treatment with azithromycin.